The latest melanoma vaccine results offer a rare mixture of breakthrough and restraint: a personalized mRNA treatment cut the risk of recurrence or death, but it has not yet established that patients will live longer.

The Australian-led phase III trial involved 1,137 people whose high-risk melanoma had been surgically removed. All received pembrolizumab, sold as Keytruda, while some also received intismeran, a vaccine designed around mutations unique to each patient’s tumor. After two years, 82% of patients given the combination were alive and recurrence-free, compared with 70% receiving pembrolizumab alone. The combination reduced the risk of recurrence or death by 42%.¹

Supporters describe the findings as a major advance in precision oncology. Georgina Long called them “a foundational shift in our approach to cancer,” while outside researcher Jessamy Tiffen said the vaccine’s “deeply personalised nature” was “truly remarkable.” Unlike therapies aimed at a single mutation, the vaccine can target up to 34 mutations in an individual tumor, training the immune system to recognize and destroy cancer cells.¹

The conservative framing is more measured, presenting the treatment chiefly as a novel vaccine that lowers the chances of melanoma tumors returning rather than as a definitive cure.² That distinction matters. Researchers say a significant share of patients do not respond initially, cancer cells can adapt, and it remains too early to determine whether the regimen improves long-term survival.¹

The results have been accepted for publication in the New England Journal of Medicine but still face peer review and regulatory scrutiny. Wider use could take years, and further research is needed to establish whether the approach works for patients with visible cancer or those who fail to respond to pembrolizumab.